GLSI Projected Dividend Yield
Greenwich LifeSciences Inc ( NASDAQ : GLSI )Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. 20 YEAR PERFORMANCE RESULTS |
GLSI Dividend History Detail GLSI Dividend News GLSI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |